Quale sarebbe il prezzo per Galmed Pharmaceuticals Ltd. (GLMD)

Il prezzo per Galmed Pharmaceuticals Ltd. (GLMD) è $0.5225

Qual è la capitalizzazione di mercato per Galmed Pharmaceuticals Ltd. (GLMD)

La capitalizzazione di mercato per Galmed Pharmaceuticals Ltd. (GLMD) è $4.32M

Galmed Pharmaceuticals Ltd. (GLMD) EPS

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Anno	EPS	Cambia
Non abbastanza dati per le date fornite.

Anno

EPS

Cambia

Non abbastanza dati per le date fornite.

Azienda	EPS	Differenza di EPS	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Azienda

EPS

Differenza di EPS

Il paese